Methazolamide: Difference between revisions
No edit summary |
No edit summary |
||
Line 48: | Line 48: | ||
* Dosing Information | * Dosing Information | ||
:* | :* '''50–100 mg two or three times daily''' | ||
<!--Off-Label Use and Dosage (Adult)--> | <!--Off-Label Use and Dosage (Adult)--> | ||
Line 73: | Line 55: | ||
|offLabelAdultGuideSupport= | |offLabelAdultGuideSupport= | ||
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients. | There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients. | ||
Line 93: | Line 61: | ||
|offLabelAdultNoGuideSupport= | |offLabelAdultNoGuideSupport= | ||
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients. | There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients. | ||
Line 110: | Line 70: | ||
|fdaLIADPed= | |fdaLIADPed= | ||
* The safety and effectiveness of methazolamide in children have not been established. | |||
* | |||
<!--Off-Label Use and Dosage (Pediatric)--> | <!--Off-Label Use and Dosage (Pediatric)--> | ||
Line 125: | Line 77: | ||
|offLabelPedGuideSupport= | |offLabelPedGuideSupport= | ||
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients. | There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients. | ||
Line 145: | Line 83: | ||
|offLabelPedNoGuideSupport= | |offLabelPedNoGuideSupport= | ||
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients. | There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients. |
Revision as of 22:58, 5 July 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Gerald Chi
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Methazolamide is a carbonic anhydrase inhibitor that is FDA approved for the {{{indicationType}}} of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit, such as chronic open-angle glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where lowering the intraocular pressure is desired before surgery.. Common adverse reactions include diarrhea, taste alterations, loss of appetite, nausea, vomiting, confusion, paresthesia, somnolence, polyuria, fatigue, and malaise.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Glaucoma
- Dosing Information
- 50–100 mg two or three times daily
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Methazolamide in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Methazolamide in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
- The safety and effectiveness of methazolamide in children have not been established.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Methazolamide in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Methazolamide in pediatric patients.
Contraindications
- Condition1
Warnings
- Description
Precautions
- Description
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Clinical Trial Experience of Methazolamide in the drug label.
Central Nervous System
Cardiovascular
Respiratory
Gastrointestinal
Hypersensitivity
Miscellaneous
Postmarketing Experience
There is limited information regarding Postmarketing Experience of Methazolamide in the drug label.
Central Nervous System
Cardiovascular
Respiratory
Gastrointestinal
Hypersensitivity
Miscellaneous
Drug Interactions
- Drug
- Description
Use in Specific Populations
Pregnancy
- Pregnancy Category
- Australian Drug Evaluation Committee (ADEC) Pregnancy Category
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Methazolamide in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Methazolamide during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Methazolamide with respect to nursing mothers.
Pediatric Use
There is no FDA guidance on the use of Methazolamide with respect to pediatric patients.
Geriatic Use
There is no FDA guidance on the use of Methazolamide with respect to geriatric patients.
Gender
There is no FDA guidance on the use of Methazolamide with respect to specific gender populations.
Race
There is no FDA guidance on the use of Methazolamide with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Methazolamide in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Methazolamide in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Methazolamide in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Methazolamide in patients who are immunocompromised.
Administration and Monitoring
Administration
- Oral
- Intravenous
Monitoring
There is limited information regarding Monitoring of Methazolamide in the drug label.
Condition1
- Description
IV Compatibility
There is limited information regarding IV Compatibility of Methazolamide in the drug label.
Overdosage
Acute Overdose
Signs and Symptoms
- Description
Management
- Description
Chronic Overdose
There is limited information regarding Chronic Overdose of Methazolamide in the drug label.
Pharmacology
Methazolamide
| |
Systematic (IUPAC) name | |
N-(3-methyl-5-sulfamoyl-3H- 1,3,4-thiadiazol-2-ylidene) ethanamide | |
Identifiers | |
CAS number | |
ATC code | S01 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | Template:OrganicBox atomTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox |
Mol. mass | 236.274 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Protein binding | 55% |
Metabolism | ? |
Half life | 14 hours |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
C(US) |
Legal status |
[[Prescription drug|Template:Unicode-only]](US) |
Routes | Oral |
Mechanism of Action
Structure
Pharmacodynamics
There is limited information regarding Pharmacodynamics of Methazolamide in the drug label.
Pharmacokinetics
There is limited information regarding Pharmacokinetics of Methazolamide in the drug label.
Nonclinical Toxicology
There is limited information regarding Nonclinical Toxicology of Methazolamide in the drug label.
Clinical Studies
There is limited information regarding Clinical Studies of Methazolamide in the drug label.
Condition1
- Description
How Supplied
Storage
There is limited information regarding Methazolamide Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Methazolamide |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Methazolamide |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Patient Counseling Information of Methazolamide in the drug label.
Precautions with Alcohol
- Alcohol-Methazolamide interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
- Neptazane®
- Glauctabs®[1]
Look-Alike Drug Names
- A® — B®[2]
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.
- ↑ Empty citation (help)
- ↑ "http://www.ismp.org". External link in
|title=
(help)
{{#subobject:
|Page Name=Methazolamide |Pill Name=No image.jpg |Drug Name= |Pill Ingred=|+sep=; |Pill Imprint= |Pill Dosage= |Pill Color=|+sep=; |Pill Shape= |Pill Size (mm)= |Pill Scoring= |Pill Image= |Drug Author= |NDC=
}}
{{#subobject:
|Label Page=Methazolamide |Label Name=Methazolamide11.png
}}
{{#subobject:
|Label Page=Methazolamide |Label Name=Methazolamide11.png
}}